✦ LIBER ✦

Adjuvant low dose radiation in childhood non-Hodgkin's lymphoma (report from the United Kingdom Childrens' Cancer Study Group--UKCCSG)

✍ Scribed by Mott, M G; Eden, O B; Palmer, M K

Book ID: 109835549
Publisher: Nature Publishing Group
Year: 1984
Tongue: English
Weight: 929 KB
Volume: 50
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.1984.202

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant low dose radiation in childhood

Adjuvant low dose radiation in childhood T cell leukaemia/lymphoma (report from the United Kingdom Childrens' Cancer Study Group--UKCCSG)

✍ Mott, M G; Chessells, J M; Willoughby, M L; Mann, J R; Morris-Jones, P H; Malpas 📂 Article 📅 1984 🏛 Nature Publishing Group 🌐 English ⚖ 771 KB

Improved outcome in children with advanc

Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol

✍ Atra, A; Imeson, J D; Hobson, R; Gerrard, M; Hann, I M; Eden, O B; Carter, R L; 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 97 KB

Acute neurotoxicity in children with adv

Acute neurotoxicity in children with advanced stage B-non-Hodgkin's lymphoma and B-acute lymphoblastic leukaemia treated with the United Kingdom children cancer study group 9002/9003 protocols

✍ A. Atra; C.R. Pinkerton; E. Bouffet; A. Norton; R. Hobson; J.D. Imeson; M. Gerra 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 151 KB

A randomized study comparing high-dose m

A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: A report from the childrens cancer study group

✍ Krailo, M. ;Ertel, I. ;Makley, J. ;Fryer, C. J. H. ;Baum, E. ;Weetman, R. ;Yunis 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 591 KB

Methotrexate (MTX) has demonstrated significant activity against relapsed and metastatic osteosarcoma. However, there is little published data to indicate the appropriate dose for MTX when given as a component of a multidrug regimen for the treatment of osteosarcoma. Therefore, the investigators at